Inhibition of abnormal ERK activities in these cancer cells by canertinib (an EGFR inhibitor), vemurafenib (a BRaf inhibitor), or trametinib (a MEK inhibitor) treatment abrogated their expression (Fig. 7e). Here, MAP2K7 is linked to cancer.